J Clin Oncol. 2004 Nov 15;22(22):4613-5. doi: 10.1200/JCO.2004.05.077. Epub 2004 Oct 4.
The following American Society of Clinical Oncology (ASCO) position statement represents an update to policy first adopted by the Board in 1997 (J Clin Oncol 15:3416-3417, 1997). The primary change to the statement is the addition of language to section 7, Standards for Antineoplastic Therapy, describing safeguards for preparing and administering chemotherapy drugs. As third-party payors consider and follow through with the establishment of new models for chemotherapy drug procurement, distribution, and delivery, ASCO provides guidance to oncologists to help them ensure the safety and integrity of the drugs they administer. Additionally, section 5, Office Operations, also suggests that oncologists consider measures protecting them from liability associated with drugs obtained from or prepared by outside entities.
以下美国临床肿瘤学会(ASCO)立场声明是对1997年董事会首次通过的政策的更新(《临床肿瘤学杂志》1997年第15卷:3416 - 3417页)。该声明的主要变化是在第7节“抗肿瘤治疗标准”中增加了有关化疗药物制备和给药保障措施的内容。随着第三方支付方考虑并实施化疗药物采购、分发和配送新模式,ASCO为肿瘤学家提供指导,以帮助他们确保所使用药物的安全性和完整性。此外,第5节“办公室运营”还建议肿瘤学家考虑采取措施,保护自己免受与从外部实体获取或由其制备的药物相关的责任风险。